文献速递心力衰竭与心肌病

组胺N-甲基转移酶上调在心肌肥厚与心力衰竭中的作用

Histamine N-methyltransferase upregulation, cardiac hypertrophy, and heart failure.
PubMed 文献 · Eur Heart J · 2026-01-01

该研究通过心肌细胞特异性敲除和过表达小鼠模型及主动脉缩窄诱导心衰,探究组胺N-甲基转移酶(HNMT)在心衰中的代谢-表观遗传机制。结果显示,心衰患者和小鼠心脏组织中HNMT上调,尿N-甲基组胺水平与心衰严重程度正相关。HNMT通过降低SAM、削弱EZH2功能并减少Fzd2启动子H3K27me3修饰,激活WNT/CaMKII通路而加重心衰;HNMT抑制剂阿莫地喹可改善小鼠心功能。

要点

  • HNMT在心衰心脏组织中上调,尿N-甲基组胺可作为无创心衰生物标志物。
  • HNMT通过SAM/FZD2/CaMKII轴促进病理性肥厚和心衰。
  • HNMT抑制剂阿莫地喹在主动脉缩窄小鼠中改善心功能。

核心结论

  • HNMT通过降低细胞内SAM、削弱EZH2功能、减少Fzd2启动子H3K27me3修饰,上调FZD2并激活WNT/CaMKII通路,加重病理性肥厚和心衰。
  • HNMT抑制剂阿莫地喹在主动脉缩窄诱导的心衰小鼠中具有治疗潜力。
  • 尿N-甲基组胺水平在心衰患者中升高且与心衰严重程度正相关,可作为无创生物标志物。

研究设计与样本

  • 研究采用心肌细胞特异性Hnmt敲除和Hnmt过表达小鼠,通过主动脉缩窄或血管紧张素II诱导心衰模型。
  • 采用RNA测序和靶向代谢组学探索机制。
  • 在53例心衰患者和55例对照人群中检测尿N-甲基组胺水平。

主要发现

  • HNMT在心衰患者心脏组织、主动脉缩窄小鼠心脏和苯肾上腺素处理的新生小鼠心肌细胞中表达上调。
  • 心衰患者尿N-甲基组胺水平升高,且与心衰严重程度呈正相关。
  • 心肌细胞特异性Hnmt缺失减轻主动脉缩窄或血管紧张素II诱导的肥厚和心衰。
  • Hnmt过表达损害小鼠心功能。
  • HNMT降低细胞内SAM水平,损害EZH2功能,减少Fzd2启动子H3K27me3修饰。

关键数值与推荐

  • 尿N-甲基组胺水平在心衰患者中升高并随病情加重而升高。
  • FZD2上调激活WNT/钙/钙调蛋白依赖性蛋白激酶II通路,促进心衰。

临床怎么用

  • 阿莫地喹可作为HNMT抑制剂,在主动脉缩窄诱导心衰中改善心功能。
  • 尿N-甲基组胺可作为无创心衰生物标志物用于评估病情严重程度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Histamine signalling is critical in heart failure (HF). Histamine N-methyltransferase (HNMT) serves as the primary enzyme responsible for histamine clearance in heart, but its role in HF remains undefined. This study investigates HNMT-mediated metabolic-epigenetic crosstalk in HF and evaluates therapeutic strategies targeting this axis. METHODS: Cardiomyocyte-specific Hnmt-knockout and Hnmt-overexpression mice were generated. Transverse aortic constriction (TAC) was applied to induce HF in mice. RNA sequencing and targeted metabolomics were employed to explore mechanisms underlying the pathological role of HNMT. Urinary N-methylhistamine levels were measured in a cohort of 53 HF and 55 control individuals. RESULTS: HNMT was up-regulated in cardiac tissues from HF patients, TAC-operated mice, and phenylephrine (PE)-treated neonatal mouse cardiomyocytes (NMCMs). Urinary N-methylhistamine levels were elevated in HF patients and positively correlated with severity of HF. In mice, cardiomyocyte-specific Hnmt deletion mitigated hypertrophy and HF induced by TAC or angiotensin II. Pharmacological HNMT inhibition with amodiaquine ameliorated TAC-induced cardiac dysfunction. Conversely, Hnmt overexpression impaired cardiac function. Mechanistically, HNMT reduced intracellular S-adenosylmethionine (SAM) and impaired enhancer of zeste homologue 2 (EZH2) function, decreasing histone 3 lysine 27 trimethylation (H3K27me3) modification at the frizzled-2 (Fzd2) promoter. FZD2 up-regulation activated the WNT/calcium/calmodulin-dependent protein kinase II (CaMKII) pathway, promoting HF. CONCLUSIONS: HNMT exacerbates pathological hypertrophy and HF through SAM/FZD2/CaMKII axis. Amodiaquine, the inhibitor of HNMT, shows therapeutic potential against HF. Urinary N-methylhistamine emerges as a non-invasive HF biomarker.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Zhang, Jiang, Liu, et al. Histamine N-methyltransferase upregulation, cardiac hypertrophy, and heart failure. Eur Heart J. 2026. PMID: 41568626. doi:10.1093/eurheartj/ehaf1065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。